Corcept Therapeutics Incorporated Common Stock CORT
i
Market dataready · fetched 2026-11-11T13:59:31.092Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:57:10.088508072Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T13:59:30.720134+00:00
Corcept Therapeutics Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 83.44 | 82.6% | 14.1% | 67.11 | 80.2% | 10.8% |
| 25Δ | 81.40 | 80.7% | 11.8% | 68.53 | 80.9% | 9.5% |
| 30Δ | 79.62 | 78.2% | 9.8% | 69.72 | 84.1% | 8.5% |
| 35Δ | 78.27 | 78.0% | 8.5% | 71.03 | 80.4% | 7.2% |
| 40Δ | 76.93 | 75.3% | 7.1% | 72.38 | 74.7% | 5.8% |
| 45Δ | 75.62 | 69.6% | 5.7% | 73.45 | 72.2% | 4.9% |
| 50Δ | 74.49 | 66.6% | 4.6% | 74.49 | 70.0% | 4.1% |
| 55Δ | 73.52 | 66.0% | 3.9% | 75.77 | 73.7% | 3.5% |
| 60Δ | 72.55 | 65.5% | 3.2% | 77.26 | 83.0% | 3.3% |
| 65Δ | 71.28 | 71.4% | 2.9% | 78.78 | 85.8% | 2.9% |
| 70Δ | 70.00 | 77.6% | 2.6% | 80.39 | 87.5% | 2.3% |
| 75Δ | 69.03 | 73.1% | 2.0% | 82.33 | 90.2% | 1.9% |
| 80Δ | 68.06 | 68.5% | 1.4% | 84.88 | 94.6% | 1.4% |
20Δ
- Pseudo strike
- 83.44
- IV
- 82.6%
- B/E move
- 14.1%
- Pseudo strike
- 67.11
- IV
- 80.2%
- B/E move
- 10.8%
25Δ
- Pseudo strike
- 81.40
- IV
- 80.7%
- B/E move
- 11.8%
- Pseudo strike
- 68.53
- IV
- 80.9%
- B/E move
- 9.5%
30Δ
- Pseudo strike
- 79.62
- IV
- 78.2%
- B/E move
- 9.8%
- Pseudo strike
- 69.72
- IV
- 84.1%
- B/E move
- 8.5%
35Δ
- Pseudo strike
- 78.27
- IV
- 78.0%
- B/E move
- 8.5%
- Pseudo strike
- 71.03
- IV
- 80.4%
- B/E move
- 7.2%
40Δ
- Pseudo strike
- 76.93
- IV
- 75.3%
- B/E move
- 7.1%
- Pseudo strike
- 72.38
- IV
- 74.7%
- B/E move
- 5.8%
45Δ
- Pseudo strike
- 75.62
- IV
- 69.6%
- B/E move
- 5.7%
- Pseudo strike
- 73.45
- IV
- 72.2%
- B/E move
- 4.9%
50Δ
- Pseudo strike
- 74.49
- IV
- 66.6%
- B/E move
- 4.6%
- Pseudo strike
- 74.49
- IV
- 70.0%
- B/E move
- 4.1%
55Δ
- Pseudo strike
- 73.52
- IV
- 66.0%
- B/E move
- 3.9%
- Pseudo strike
- 75.77
- IV
- 73.7%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 72.55
- IV
- 65.5%
- B/E move
- 3.2%
- Pseudo strike
- 77.26
- IV
- 83.0%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 71.28
- IV
- 71.4%
- B/E move
- 2.9%
- Pseudo strike
- 78.78
- IV
- 85.8%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 70.00
- IV
- 77.6%
- B/E move
- 2.6%
- Pseudo strike
- 80.39
- IV
- 87.5%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 69.03
- IV
- 73.1%
- B/E move
- 2.0%
- Pseudo strike
- 82.33
- IV
- 90.2%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- 68.06
- IV
- 68.5%
- B/E move
- 1.4%
- Pseudo strike
- 84.88
- IV
- 94.6%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 66.40% | |
| 68.06% | |
| 67.56% | |
| 68.78% | |
| 79.88% | |
| 81.37% | |
| 83.03% | |
| 86.33% | |
| 85.20% | |
| 87.04% |
Biotechnology
COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid…
More →CRBU
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies…
More →CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
More →CRMD
Description unavailable
More →CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →